IDEAYA Biosciences Reports Material Definitive Agreement; Details Undisclosed

TL;DR

**IDYA just signed a big deal, but they're not telling us what it is yet.**

AI Summary

IDEAYA Biosciences, Inc. filed an 8-K on January 19, 2024, to report an "Entry into a Material Definitive Agreement." While the filing confirms the agreement's existence, it does not disclose the specific details, parties, or financial terms of this agreement. This matters to investors because material definitive agreements can significantly impact a company's future operations, financial health, and stock valuation, and the lack of specifics creates uncertainty.

Why It Matters

This filing signals a significant business development for IDEAYA Biosciences, Inc., but the absence of details means investors are currently in the dark about its potential impact on the company's future prospects and stock price.

Risk Assessment

Risk Level: medium — The lack of specific details regarding a 'Material Definitive Agreement' introduces uncertainty, as the agreement could be highly beneficial or detrimental to the company.

Analyst Insight

A smart investor would monitor subsequent filings or press releases from IDEAYA Biosciences, Inc. for specific details about the 'Material Definitive Agreement' before making any investment decisions, as the current filing lacks actionable information.

Key Players & Entities

• IDEAYA Biosciences, Inc. (company) — the registrant filing the 8-K
• January 19, 2024 (date) — date of the earliest event reported
• 001-38915 (string) — Commission File Number for IDEAYA Biosciences, Inc.
• IDYA (string) — Trading Symbol for IDEAYA Biosciences, Inc.
• The Nasdaq Global Select Market (string) — exchange where IDEAYA Biosciences, Inc. common stock is registered

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IDYA The Nasdaq
• $350.0 million — aving aggregate gross proceeds of up to $350.0 million (the "Shares") through Jefferies as its

Filing Documents

• d581989d8k.htm (8-K) — 28KB
• d581989dex51.htm (EX-5.1) — 12KB
• d581989dex101.htm (EX-10.1) — 207KB
• g581989dsp4.jpg (GRAPHIC) — 8KB
• g581989dsp4a.jpg (GRAPHIC) — 8KB
• 0001193125-24-011346.txt ( ) — 448KB
• idya-20240119.xsd (EX-101.SCH) — 3KB
• idya-20240119_lab.xml (EX-101.LAB) — 18KB
• idya-20240119_pre.xml (EX-101.PRE) — 11KB
• d581989d8k_htm.xml (XML) — 3KB

01

Item 1.01 Entry into a Material Definitive Agreement On January 19, 2024, IDEAYA Biosciences, Inc. (the "Company") entered into an Open Market Sales Agreement (the "Sales Agreement") with Jefferies LLC ("Jefferies"), with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the "Common Stock"), having aggregate gross proceeds of up to $350.0 million (the "Shares") through Jefferies as its sales agent. Under the Sales Agreement, the Company will set the parameters for the sale of Shares, including the number of Shares to be issued, the time period during which sales are requested to be made, limitations on the number of Shares that may be sold in any one trading day and any minimum price below which sales may not be made. Subject to the terms of the Sales Agreement, Jefferies may sell the Shares by any method that is deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the "Securities Act"), including sales made directly on The Nasdaq Global Select Market or any other trading market for the Common Stock. The Company will pay Jefferies a commission of up to three percent (3.0%) of the gross sales proceeds of any Shares sold through Jefferies under the Sales Agreement, and has provided Jefferies with customary indemnification and contribution rights. The Sales Agreement will terminate upon the earlier of (i) the sale of all Shares subject to the Sales Agreement or (ii) termination of the Sales Agreement in accordance with its terms. Any Shares to be offered and sold under the Sales Agreement will be issued and sold pursuant to the Company's Registration Statement on Form S-3 (File No. 333-272936), which became automatically effective upon its filing on June 26, 2023. The Company filed a prospectus supplement with the Securities and Exchange Commission on J

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Latham & Watkins LLP. 10.1 Open Market Sales Agreement, dated as of January 19, 2024, by and between the Company and Jefferies LLC. 23.1 Consent of Latham & Watkins LLP (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEAYA BIOSCIENCES, INC. Date: January 19, 2024 By: /s/ Yujiro Hata Yujiro Hata President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR